Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients.
about
Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancerImpact of effective prevention and management of febrile neutropenia.Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study.Neutropenia: occurrence and management in women with breast cancer receiving chemotherapyPegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL StudyDoes chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.Prognostic value of chemotherapy-induced leukopenia in small-cell lung cancer.Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors.Management of chemotherapy-associated febrile neutropenia.Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim.The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.Adjuvant systemic therapy for elderly women with breast cancer.Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia.FOLFOX chemotherapy can safely be given to neutropenic patients with early-stage colorectal cancer for higher dose intensity and fewer visits.Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN.Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy.Efficacy of reduced dose of pegfilgrastim in Japanese breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide therapy.Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer1-Pamitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol May Reduce Incidence of Gemcitabine-Induced Neutropenia: A Pilot Case-Controlled Study.Breast cancer: Improved care through effective management of febrile neutropenia. Foreword.Relative dose intensity in early stage breast cancer chemotherapy: A retrospective analysis of incidence, risk factors and outcomes at a south-west Sydney cancer clinic.Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer.NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.Chemotherapy appointment scheduling under uncertainty using mean-risk stochastic integer programming.Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe.
P2860
Q33397995-7260242F-0286-4975-8E24-C7FC351041FAQ33503548-3AEF5C80-75FC-4506-8FD9-10DF9BFA5A85Q33543823-F0246F59-17AA-4F07-8D71-2673408A72D8Q34934481-8C52D7A9-01BE-4F4B-A401-9DC4723C94E6Q35860879-CEC66E6E-E049-41EB-B68D-C5DBA9AB721EQ36243957-28FE891F-27C1-4979-A913-6C45F54CA7E2Q36610747-F1032944-0C73-4549-98B3-31736FDDF55EQ36885665-314CCECA-B89E-4BD6-B845-19813DD1CE3EQ37034836-96FD713E-2350-4272-83D5-E8445915475DQ37363332-8DE9E5B0-2A3C-4B95-BA00-E9D05E241D1BQ37363344-CE3C1CD2-A82B-4344-970F-52CE0D517A0DQ37391741-CC99BBBC-EBC7-42BA-895C-BB1A67F14300Q37607276-B105B95D-CE32-49B1-BB3A-B132847C0D6AQ37608377-623A362A-13A5-4C15-8DE2-1DB61FC2F2A5Q37831314-706AA51E-4595-4EC2-8FE3-6D588D3D4614Q38109529-D85DA7C1-8CAA-4020-A5F9-F3A88878B0D5Q38676386-18C6CFC3-B360-4077-A6D1-DCADE0A79E04Q39074316-90FC59B8-AB40-415D-8268-6770254CC0D8Q40137270-CA15A80E-FE9E-4B62-8395-9B509D93E13CQ40316147-E526F682-240A-4C0A-94D1-D93E0BBE71EDQ40364449-D0CC78FC-977C-4CA8-BCAD-E69616A0B910Q41684418-64A1DA7C-0841-4A65-98B8-4456A08F2520Q41958401-AC7D7F14-C61C-4168-A31E-245D9D75C2C4Q42566681-EF46A41D-42CE-428F-AC3B-9AB3C2368E6FQ44212969-9CF50F0B-817B-40E1-85B8-17834B3F4FAAQ45848898-B63E4553-05CE-4997-9BF9-FA24685DC1B9Q49937810-3613828E-E496-4B6F-96F5-FAAEB3602732Q50582651-AB04EA1F-DED4-47C6-A64B-506623CB0880Q53534502-C4CFA3D1-D503-49EA-8FB5-FD09E13F47DC
P2860
Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Impact of neutropenia on deliv ...... rimary breast cancer patients.
@ast
Impact of neutropenia on deliv ...... rimary breast cancer patients.
@en
type
label
Impact of neutropenia on deliv ...... rimary breast cancer patients.
@ast
Impact of neutropenia on deliv ...... rimary breast cancer patients.
@en
prefLabel
Impact of neutropenia on deliv ...... rimary breast cancer patients.
@ast
Impact of neutropenia on deliv ...... rimary breast cancer patients.
@en
P2093
P2860
P356
P1476
Impact of neutropenia on deliv ...... rimary breast cancer patients.
@en
P2093
R C F Leonard
UK Breast Cancer Neutropenia Audit Group
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601279
P407
P577
2003-12-01T00:00:00Z